Skip to content

Effect of Phosphorus Supplementation on Body Weight

Premeal Phosphorus Supplementation for Reducing Energy Intake and Body Weight

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02329990
Enrollment
71
Registered
2015-01-01
Start date
2013-06-30
Completion date
2014-09-30
Last updated
2016-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Body Weight

Keywords

phosphorus intake

Brief summary

Phosphorus is a mineral that is naturally present in our foods and is required by our bodies for normal function. It has been found that phosphorus supplementation taken before meals has the potential to reduce meal size. However its long term effect has not been measured yet. It is well accepted that changes in body weight require about 3 months. Using body weight as the outcome, which is the ultimate outcome of weight loss approaches, would provide robust information on the role of phosphorus.

Detailed description

A double-blind, randomised, placebo-controlled trial of 63 adults aged 18 to 45 years with a body mass index (BMI) of 25 kg/m2 or higher and normal kidney function at the American University of Beirut. Participants were randomly assigned to the placebo or phosphorus group where daily placebo or phosphorus supplements were ingested with three main meals (breakfast, lunch, and dinner) for a period of 12 weeks. Primary outcomes were changes in anthropometric measures, blood metabolites (including lipid profile, glucose, and insulin), and subjective appetite scores.

Interventions

DIETARY_SUPPLEMENTphosphorus

phosphorus supplement

Sponsors

American University of Beirut Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* BMI\>25 * CR\>1mg/dl for women; Cr \>1.2 mg/dl for men * GFR \>60ml/min/1.73m2

Exclusion criteria

* BMI\<25 * presence of any significant medical disease, * pregnancy or lactation, * regular administration of drugs that affect body weight, and * weight loss of 3% or more within 3 months of study entry.

Design outcomes

Primary

MeasureTime frame
Body Weight3 months

Secondary

MeasureTime frame
Waist Circumference3 months
Appetite Score on the Visual Analog Scale6 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026